DIPTHERIA, TETANUS, PERTUSSIS, HEPATITIS B, POLIOMYELITIS AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE (DTaP-HB-IPV-Hib)

Information current as at: 1 August 2026

The processes outlined in the MSW are not applicable to this medicine. Please contact pbs@health.gov.au or 1800 020 613 for further information.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Vaxelis®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: sanofi-aventis Australia Pty Ltd
Condition/indication: (therapeutic use): Diptheria; tetanus; pertussis; hepatitis B; poliomyelitis and Haemophilus influenzae type b
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: March 2022 PBAC meeting
Opportunity for consumer comment:: Open 24/11/2021 and close 27/01/2022 (see PBS Website)
PBAC meeting:: Held on 09/03/2022
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Not Applicable
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a465

Page last updated

20 March 2024

v.9.16